Associated tags: Patient, Vaccinia, CHOICE, DNA, Engineering, Genelux Corporation, Pharmaceutical industry, Safety
Locations: WESTLAKE VILLAGE, CA, US, CHINA, UNITED STATES
Investment,
Research,
Security (finance),
Guggenheim Partners,
Lung cancer,
Carcinoma,
Form,
Patient,
Genelux Corporation,
S-3,
Clinical trial,
G&A,
Platinum,
Pharmaceutical industry WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.
Key Points:
- WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.
- In the first quarter of 2024, we filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission.
- Research and development (R&D) expenses were $4.0 million for the first quarter of 2024, as compared to $2.8 million for the first quarter 2023, respectively.
- General and administrative (G&A) expenses were $4.1 million in the first quarter of 2024, as compared to $3.8 million for the first quarter of 2023.
Research,
Lung cancer,
Medical school,
Shanghai Jiao Tong University,
Carcinoma,
Fast track (FDA),
Form,
Patient,
G&A,
School,
IPO,
Hope,
Security (finance),
Guggenheim Partners,
Investment,
Platinum,
Interim,
Genelux Corporation,
FDA,
Pharmaceutical industry WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.
Key Points:
- – $23.2 million in cash, cash equivalents and short-term investments –
WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.
- Currently, 21 sites have been activated to enroll patients with additional sites identified and in various stages of activation ( NCT05281471 ).
- Genelux and our partner Newsoara co-sponsor the trial, which is being conducted by Newsoara in greater China.
- Cash, cash equivalents and short-term investments were $23.2 million as of December 31, 2023 compared to $0.4 million on December 31, 2022.
Retrieved on:
Monday, November 27, 2023
WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.
Key Points:
- WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.
- “The Fast Track designation granted for Olvi-Vec underscores its potential to address unmet medical needs in ovarian cancer, a significant recognition as we continue to enroll our Phase 3 OnPrime study,” said Thomas Zindrick , President, Chairman and CEO of Genelux.
- The purpose of Fast Track designation is to facilitate the development and hasten the review process of drugs aimed at treating serious and life-threatening conditions, ensuring that an approved product can swiftly enter the market.
- Notable aspects of Fast Track designation encompass regular engagements with the FDA review team, and, if specific criteria are satisfied, potential eligibility for Priority Review and Rolling Review.
Retrieved on:
Tuesday, November 14, 2023
Accounting,
Safety,
D,
Platinum,
Carcinoma,
Sonifi Solutions,
CFO,
Patient,
Investment,
Research,
IPO,
Financial management,
Hand,
Amgen,
Pharmaceutical industry,
Genelux Corporation WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates.
Key Points:
- WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates.
- R&D Expenses: Research and development expenses were $2.8 million for the third quarter of 2023, as compared to $2.4 million for the third quarter of 2022.
- G&A Expenses: General and administrative expenses were $2.5 million for the third quarter of 2023, as compared to $2.2 million for the third quarter of 2022.
- Net Loss: Net loss was $5.3 million for the third quarter of 2023, as compared to net income of $4.9 million for the third quarter of 2022.
Retrieved on:
Thursday, September 14, 2023
The Board approved the awards as an inducement material to such new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Key Points:
- The Board approved the awards as an inducement material to such new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
- Each stock option has an exercise price per share equal to $22.40 per share, the Company’s closing sales price on September 11, 2023.
- Each stock option will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates.
- The awards are subject to the terms and conditions of the Company’s 2023 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
Retrieved on:
Thursday, September 7, 2023
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11th, 2023.
Key Points:
- WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11th, 2023.
- The Company will also attend virtual one-on-one meetings during the conference.
- Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference virtually or contact [email protected].
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.
Key Points:
- WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.
- "I am excited to welcome Lourie to Genelux as our new Chief Financial Officer," said Thomas Zindrick , President, Chairman and CEO of Genelux.
- Ms. Zak will join Genelux with an extensive background in CFO roles, including Guitar Center Brands, Sonifi Solutions, and PBS Biotech.
- Doug Samuelson, who played an important role as the Company’s Chief Financial Officer during its IPO earlier this year, is set to resume his position as Vice President of Finance.
IPO,
Senior,
Investment,
Head,
JAMA,
Clinical trial,
Drug,
Article,
MS,
American Medical Association,
Journal,
Russell,
Patient,
Patent,
Regulatory affairs,
Research,
Pharmaceutical Development and Technology,
Safety,
D,
Pharmaceutical industry,
Genelux Corporation,
Q2,
NSCLC,
Quality,
MD WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2023 and provided general business updates.
Key Points:
- - $51 Million raised after closing of two private placements in Q2, totaling $65 million raised in the first half of 2023 -
WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2023 and provided general business updates.
- R&D Expenses: Research and development expenses were $2.9 million for the second quarter of 2023, as compared to $1.8 million for the second quarter of 2022.
- G&A Expenses: General and administrative expenses were $2.5 million for the second quarter of 2023, as compared to $1.0 million for the second quarter of 2022.
- Net Loss: Net loss was $5.8 million for the second quarter of 2023, as compared to a net loss of $2.8 million for the second quarter of 2022.
Retrieved on:
Wednesday, August 2, 2023
WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023.
Key Points:
- WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023.
- The conversation with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, is scheduled to begin at 4:00 p.m.
- ET on Tuesday, August 8, 2023.
Inflammation,
Amgen,
Genelux Corporation,
Senior,
Marketing,
International Safety Equipment Association,
Head,
American Society of Clinical Oncology,
Drug,
Research,
Consultant,
Trial of the century,
MS,
Clinical trial,
Regulatory affairs,
Pharmaceutical Development and Technology,
Society,
Regulation,
Ecologically based invasive plant management,
Pharmaceutical industry,
Medical device,
Quality Tony Yu, Ph.D., formerly the Company’s Vice President of Clinical Trial Operations, has been promoted to Senior Vice President of Clinical Development.
Key Points:
- Tony Yu, Ph.D., formerly the Company’s Vice President of Clinical Trial Operations, has been promoted to Senior Vice President of Clinical Development.
- Ralph Smalling, MS has joined the Company as Head of Regulatory and Caroline Jewett has joined the Company as Head of Quality.
- Dr. Cappello has served as Vice President of Pharmaceutical Development since November 2012 and General Manager of Manufacturing Facility since September 2018.
- Dr. Yu has served as the Vice President of Clinical Trial Operations since January 2010, and was the first employee of Genelux in 2002.
